James Waldron

Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high-risk human papillomavirus (hrHPV)-associated cervical cancer is safe.

Boehringer Ingelheim is making yet

Cidara Therapeutics already knew that Janssen planned to hand off its obligations to their flu prophylaxis candidate to another entity. Now it turns out that entity will be …Cidara.

Eagle-eyed watchers of Deloitte's annual reports on Big Pharma will have noticed a depressing trend—ever-increasing costs for developing drugs over the past decade as the return on investment sinks.

Both Destiny Pharma and Santhera Pharmaceuticals used their earnings announcements this morning to explain why a tighter clinical focus will come at the expense of one of their potential assets.

Addex Therapeutics’ run of bad luck in the clinic shows no sign of ending, as a Janssen-licensed epilepsy drug has failed to reduce the occurrence of seizures in a phase 2 trial.

Japan’s Ono Pharmaceutical is

Eli Lilly’s explosion into the weight loss space is proving fruitful for shareholders, but it’s also providing fresh opportunities for biotechs looking for a Big Pharma partnership.

With $6.5 million in seed funding, Pepper Bio has decided to shake up its portfolio

Delegates at the LSX World Conference in London this week seemed to agree on one thing—the biotech IPO window finally re-opened this year.